Results 201 to 210 of about 1,757,232 (357)

Autoimmune Acquired Factor V Deficiency in a Patient With Pancreatic Cancer Complicated by Cholangitis: A Rare Coagulopathy With a Favorable Course. [PDF]

Cureus
Ueda T, Miyagawa K, Nakanishi T, Tsukada J, Harada M.   +4 more
europepmc   +1 more source

Heterozygous large deletion mimicking homozygous substitution in MCFD2 in a patient with combined Factor V and Factor VIII deficiency [PDF]

Hamdi Rezigue, Pierre Chamouni, Mathilde Frétigny, Virginie Barbay, Véronique Le Cam‐Duchez, Victor Bobée, Simon Lanne, C. Dumesnil, Christine Vinciguerra, Pascale Schneider, Yohann Jourdy   +10 more
openalex   +1 more source

Homozygous Cystathionine β-Synthase Deficiency, Combined With Factor V Leiden or Thermolabile Methylenetetrahydrofolate Reductase in the Risk of Venous Thrombosis [PDF]

, 1998
Leo A. J. Kluijtmans, Godfried H.J. Boers, Bert Verbruggen, Frans J.M. Trijbels, I.R.O. Nováková, Henk J. Blom   +5 more
openalex   +1 more source

Modeling hepatic fibrosis in TP53 knockout iPSC‐derived human liver organoids

Molecular Oncology, EarlyView.
This study developed iPSC‐derived human liver organoids with TP53 gene knockout to model human liver fibrosis. These organoids showed elevated myofibroblast activation, early disease markers, and advanced fibrotic hallmarks. The use of profibrotic differentiation medium further amplified the fibrotic signature seen in the organoids.
Mustafa Karabicici, Soheil Akbari, Ceyda Caliskan, Canan Celiker, Ozden Oz, Leman Binokay, Gökhan Karakulah, Serif Senturk, Esra Erdal   +8 more
wiley   +1 more source

Novel functional defect in factor V deficiency [PDF]

, 2003
William H. Kane
openalex   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Successful Hemostasis With Platelet Transfusion and Tranexamic Acid, and Inhibitor Elimination With Cyclosporine, in Steroid-Resistant Acquired Coagulation Factor V Deficiency Caused by Antibiotic Readministration. [PDF]

Case Rep Hematol
Togitani K, Yamamoto M, Tanaka S, Aono R, Uemura Y.   +4 more
europepmc   +1 more source

FAMILIAR CONGENITAL FACTOR V DEFICIENCY (PARAHEMOPHILIA)

Nihon Naika Gakkai Zasshi, 1965
M, Tango, A, Ujiie, N, Ishikawa, T, Yasukouchi   +3 more
openaire   +3 more sources

Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms.

Blood, 2010
C. Duckers, P. Simioni, L. Spiezia, C. Radu, P. Dabrilli, S. Gavasso, J. Rosing, E. Castoldi   +7 more
semanticscholar   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source